Invizyne Technologies (IZTC) Stock Price, News & Analysis

Company Overview

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Key Stats

• Today's Range: $16.66 to $19.69
• 50-Day Range: $10.46 to $20.52
• 52-Week Range: $8.50 to $23.00
• Volume: 8,665 shs
• Average Volume: 29,562 shs
• Market Capitalization: $105.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IZTC Stock Analysis - Frequently Asked Questions

How have IZTC shares performed this year?

Invizyne Technologies' stock was trading at $16.50 at the beginning of 2025. Since then, IZTC stock has increased by 2.4% and is now trading at $16.90.
View the best growth stocks for 2025 here.

When did Invizyne Technologies IPO?

Invizyne Technologies (IZTC) raised $15 million in an initial public offering on Wednesday, November 13th 2024. The company issued 1,875,000 shares at a price of $8.00 per share.

When does the company's lock-up period expire?

Invizyne Technologies' lock-up period expires on Monday, May 12th. Invizyne Technologies had issued 1,875,000 shares in its public offering on November 13th. The total size of the offering was $15,000,000 based on an initial share price of $8.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Who are Invizyne Technologies' major shareholders?

Top institutional shareholders of Invizyne Technologies include Citadel Advisors LLC (0.44%), Geode Capital Management LLC (0.27%) and BNP Paribas Financial Markets (0.03%).
View institutional ownership trends.

How do I buy shares of Invizyne Technologies?

Shares of IZTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 3/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IZTC
• Previous Symbol: NASDAQ:IZTC
• CIK: 2010788
• Web: www.invizyne.com
• Phone: 626-415-1488
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,252,000
• Free Float: N/A
• Market Cap: $105.66 million
• Optionable: N/A
• Beta: N/A